Allegro Ophthalmics Overview

  • Founded
  • 2011
Founded
  • Status
  • Private
  • Employees
  • 9
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $28.5M
Latest Deal Amount
  • Investors
  • 2

Allegro Ophthalmics General Information

Description

Operator of a late-stage ophthalmic biopharmaceutical company intended to redefine the retina space with integrin inhibition therapy. The company's lead investigational drug is a broad-spectrum integrin inhibitor, downregulates oxidative stress upstream, at its source, and simultaneously affecting all four pathways of oxidative stress that contribute to retinal diseases such as diabetic macular edema (DME) and nonexudative age-related macular degeneration, enabling ophthalmologist to treat ocular diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 31473 Rancho Viejo Road
  • Suite 204
  • San Juan Capistrano, CA 92675
  • United States
+1 (949) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Allegro Ophthalmics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 09-Sep-2021 $28.5M 000.00 Completed Clinical Trials - Phase 1
4. Later Stage VC 09-Jul-2017 000.00 000.00 Completed Clinical Trials - Phase 1
3. Grant 03-Feb-2015 000 000.00 Completed Clinical Trials - Phase 1
2. Early Stage VC 26-Jan-2015 $20.3M $21.8M Completed Clinical Trials - Phase 1
1. Angel (individual) 01-Apr-2012 $1.5M $1.5M Completed Clinical Trials - Phase 1
To view Allegro Ophthalmics’s complete valuation and funding history, request access »

Allegro Ophthalmics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a late-stage ophthalmic biopharmaceutical company intended to redefine the retina space with integrin inhibi
Drug Discovery
San Juan Capistrano, CA
9 As of 2022
000.00
0000000000 0 000.00

000 0000

fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia des
0000000000000
Ann Arbor, MI
00 As of 0000
000.00
00000000000 000.00

00000000

quat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla p
0000 000000000
Paris, France
00 As of 0000
0000
00.00 0000-00-00
00000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Allegro Ophthalmics Competitors (25)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ONL Therapeutics Venture Capital-Backed Ann Arbor, MI 00 000.00 00000000000 000.00
000000000 Venture Capital-Backed Paris, France 00 0000 00000000000 0000
0000000 Venture Capital-Backed Cambridge, United Kingdom 00 00.000 0000000000 0 00.000
0000 0000000000000 Formerly VC-backed Arlington, MA 000 00000 000000 - 000 00000
0000000 0000000000 Formerly VC-backed Redwood City, CA 000 00000 00000000000 00000
You’re viewing 5 of 25 competitors. Get the full list »

Allegro Ophthalmics Patents

Allegro Ophthalmics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3134362-A1 Compositions and methods useable for treatment of dry eye Pending 22-Apr-2019 000000000
US-20200345805-A1 Compositions and methods useable for treatment of dry eye Pending 22-Apr-2019 000000000

Allegro Ophthalmics Executive Team (8)

Name Title Board Seat Contact Info
Hampar Karageozian Ph.D Co-Founder, Co-Chief Executive Officer, Executive Chairman, Chief Technical Officer & President
Vicken Karageozian MD Co-Founder, Co-Chief Executive Officer & President
John Park Ph.D Co-Founder, Chief Scientific Officer, Vice President, Manufacturing Development & Executive Board Member
Stephanie Yee Vice President, Finance
William Link Chairman
You’re viewing 5 of 8 executive team members. Get the full list »

Allegro Ophthalmics Board Members (11)

Name Representing Role Since
Marc Carlson Allegro Ophthalmics Board Member 000 0000
Mark Livingston Allegro Ophthalmics Board Member 000 0000
Rebecca Colbert Self Board Member 000 0000
Ronald Kurtz Allegro Ophthalmics Board Member 000 0000
Thomas Bender Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Allegro Ophthalmics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Allegro Ophthalmics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
The Leona M. and Harry B. Helmsley Charitable Trust Lender/Debt Provider 000 0000 000000 0
Hanmi Pharmaceuticals Corporation Minority 000 0000 000000 0
To view Allegro Ophthalmics’s complete investors history, request access »